CooperCompanies Announces First Quarter 2025 ResultsSAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025.
CooperCompanies Announces Release Date for First Quarter 2025SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
CooperCompanies to Present at the J.P. Morgan Healthcare ConferenceSAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET.
CooperCompanies Announces Fourth Quarter and Full Year 2024 ResultsSAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024.
CooperCompanies Announces Release Date for Fourth Quarter and Full Year 2024SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
CooperCompanies Recognized as a Best Workplace for InnovatorsLeading global medical device company recognized for culture that drives innovation for customers and patients
CooperSurgical Launches Paragard® Intrauterine Copper Contraceptive with New Single-Hand Inserter
CooperSurgical, a global leader in women’s healthcare, today announced the launch of a new inserter designed for single-hand placement of Paragard®, which was recently approved by the U.S. Food and Drug Administration (FDA). The new single-hand inserter simplifies the placement process for healthcare providers, making Paragard an even more accessible contraceptive choice for both providers and patients. Paragard, the #1 prescribed copper intrauterine device (IUD), is a tried and true, non-hormonal contraceptive option with more than 30 years of clinical use.
CooperCompanies Announces Third Quarter 2024 ResultsSAN RAMON, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2024.
CooperCompanies to Participate in Upcoming Investor ConferencesSAN RAMON, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced its participation in the following upcoming investor conferences:
CooperCompanies Announces Release Date for Third Quarter 2024SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
CooperCompanies Acquires obp Surgical, Expanding CooperSurgical’s Portfolio of Leading Medical DevicesSAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100 million. The products being acquired generated approximately $14.5 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper’s non-GAAP earnings per share in fiscal 2024 and accretive thereafter.
